Bioventus (BVS) Competitors

Bioventus presently has a consensus price target of $14.00, suggesting a potential upside of 31.09%. LeMaitre Vascular has a consensus price target of $105.80, suggesting a potential downside of 5.54%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than LeMaitre Vascular.

Bioventus has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.

62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LeMaitre Vascular has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

LeMaitre Vascular has a net margin of 23.13% compared to Bioventus' net margin of 4.00%. Bioventus' return on equity of 28.88% beat LeMaitre Vascular's return on equity.

In the previous week, LeMaitre Vascular had 12 more articles in the media than Bioventus. MarketBeat recorded 14 mentions for LeMaitre Vascular and 2 mentions for Bioventus. LeMaitre Vascular's average media sentiment score of 1.02 beat Bioventus' score of 0.59 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Warby Parker presently has a consensus price target of $28.09, suggesting a potential upside of 29.80%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 31.09%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Warby Parker.

Bioventus has lower revenue, but higher earnings than Warby Parker. Bioventus is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Warby Parker has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Bioventus has a net margin of 4.00% compared to Warby Parker's net margin of 0.19%. Bioventus' return on equity of 28.88% beat Warby Parker's return on equity.

In the previous week, Warby Parker had 8 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for Warby Parker and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.59 beat Warby Parker's score of 0.48 indicating that Bioventus is being referred to more favorably in the news media.

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 18.2% of Warby Parker shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 2.8% of AxoGen shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bioventus has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 6.31%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 31.09%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than AxoGen.

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500.

In the previous week, AxoGen had 21 more articles in the media than Bioventus. MarketBeat recorded 23 mentions for AxoGen and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.59 beat AxoGen's score of 0.00 indicating that Bioventus is being referred to more favorably in the news media.

Bioventus has a net margin of 4.00% compared to AxoGen's net margin of -13.21%. Bioventus' return on equity of 28.88% beat AxoGen's return on equity.

Bioventus has a net margin of 4.00% compared to Establishment Labs' net margin of -24.19%. Bioventus' return on equity of 28.88% beat Establishment Labs' return on equity.

Bioventus has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Establishment Labs has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Establishment Labs currently has a consensus price target of $86.86, suggesting a potential upside of 22.35%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 31.09%. Given Bioventus' stronger consensus rating and higher possible upside, analysts clearly believe Bioventus is more favorable than Establishment Labs.

In the previous week, Establishment Labs had 12 more articles in the media than Bioventus. MarketBeat recorded 14 mentions for Establishment Labs and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.59 beat Establishment Labs' score of 0.41 indicating that Bioventus is being referred to more favorably in the news media.